Alpha Tau Medical Ltd. Ordinary Shares - DRTS STOCK NEWS

Welcome to our dedicated page for Alpha Tau Medical Ltd. Ordinary Shares news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical Ltd. Ordinary Shares stock.

Alpha Tau Medical Ltd. (NASDAQ: DRTS) is at the forefront of oncology therapeutics, specializing in the research, development, and potential commercialization of the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology. Founded in 2016, this Israeli medical device company focuses on the innovative use of alpha radiation to treat solid tumors. The Alpha DaRT technology, initially developed at Tel Aviv University, has shown promising results in preclinical and early clinical trials for various types of cancer.

Core Business and Technology: The Alpha DaRT technology uses alpha-emitting radium-224 atoms to target and destroy cancer cells while sparing surrounding healthy tissue. This method involves inserting radioactive seeds into the tumor, which release short-lived alpha particles. These particles have high biological effectiveness and a short range, making them ideal for localized treatment of solid tumors.

The company's current clinical trials are focused on multiple cancer types, including pancreatic, liver, and recurrent cutaneous squamous cell carcinoma. These trials are being conducted in various locations, including the European Union and North America. Notably, Alpha Tau is advancing its pivotal U.S. multi-center trial, ReSTART, which aims to treat recurrent cutaneous squamous cell carcinoma, and is expected to produce significant data by 2024.

Recent Achievements: Alpha Tau has made substantial progress recently. In October 2023, the company announced a long-term lease agreement for a new manufacturing site in Hudson, New Hampshire, which will significantly boost its production capabilities. Additionally, the company reported promising interim results from its pancreatic cancer trial and treated its first patient with liver metastases in a feasibility and safety study in Montreal, Canada.

Financial Condition: As of September 30, 2023, the company reported cash, restricted cash, and deposits totaling $90.1 million, ensuring sufficient funds to support operations for at least two years. For the nine months ended September 30, 2023, R&D expenses were $18.9 million, reflecting increased investments in employee compensation, clinical trials, and pre-clinical studies.

Partnerships and Collaborations: Alpha Tau is also exploring strategic partnerships to expand its clinical and commercial footprint. Discussions with major biopharmaceutical companies are underway, particularly for the Japanese market, where the company has completed a successful clinical trial for head and neck cancers.

Forward-Looking Statements: The company remains committed to advancing its clinical programs and expanding its manufacturing capabilities. With a strong financial position and a pipeline of promising clinical trials, Alpha Tau is well-positioned to make significant strides in the fight against cancer.

For more information, visit Alpha Tau Medical Ltd.